Shaker Investments LLC OH trimmed its position in Medpace Holdings, Inc. (NASDAQ:MEDP – Get Rating) by 7.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 11,786 shares of the company’s stock after selling 965 shares during the period. Medpace comprises approximately 1.6% of Shaker Investments LLC OH’s holdings, making the stock its 20th largest holding. Shaker Investments LLC OH’s holdings in Medpace were worth $2,503,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently bought and sold shares of the company. Picton Mahoney Asset Management bought a new position in Medpace in the 4th quarter valued at $42,000. Credit Suisse AG boosted its position in shares of Medpace by 5.8% in the 4th quarter. Credit Suisse AG now owns 28,518 shares of the company’s stock worth $6,058,000 after purchasing an additional 1,556 shares during the last quarter. Forte Capital LLC ADV boosted its position in shares of Medpace by 10.1% in the 4th quarter. Forte Capital LLC ADV now owns 2,951 shares of the company’s stock worth $627,000 after purchasing an additional 271 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Medpace by 9.6% in the 4th quarter. Geode Capital Management LLC now owns 585,815 shares of the company’s stock worth $124,432,000 after purchasing an additional 51,462 shares during the last quarter. Finally, American Century Companies Inc. boosted its position in shares of Medpace by 41.8% in the 4th quarter. American Century Companies Inc. now owns 7,249 shares of the company’s stock worth $1,540,000 after purchasing an additional 2,137 shares during the last quarter. 82.49% of the stock is currently owned by institutional investors.
Insider Buying and Selling at Medpace
In other Medpace news, CEO August J. Troendle sold 31,648 shares of Medpace stock in a transaction dated Tuesday, April 25th. The stock was sold at an average price of $221.83, for a total value of $7,020,475.84. Following the sale, the chief executive officer now owns 6,451,371 shares of the company’s stock, valued at approximately $1,431,107,628.93. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 25.70% of the company’s stock.
Wall Street Analysts Forecast Growth
MEDP has been the topic of several recent research reports. Robert W. Baird raised their price target on Medpace from $226.00 to $233.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 15th. 22nd Century Group restated an “upgrade” rating on shares of Medpace in a research report on Monday, May 8th. Guggenheim upgraded Medpace from a “neutral” rating to a “buy” rating and set a $252.00 price target on the stock in a research report on Monday, May 8th. Finally, StockNews.com upgraded Medpace from a “hold” rating to a “buy” rating in a research report on Friday, May 12th. Two analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, Medpace currently has a consensus rating of “Moderate Buy” and a consensus target price of $241.00.
Medpace Stock Up 1.2 %
Medpace stock traded up $2.52 during mid-day trading on Friday, hitting $209.41. 81,641 shares of the company’s stock were exchanged, compared to its average volume of 328,932. The firm has a market capitalization of $6.39 billion, a P/E ratio of 26.19 and a beta of 1.41. Medpace Holdings, Inc. has a fifty-two week low of $130.79 and a fifty-two week high of $241.48. The company’s 50 day simple moving average is $198.62 and its 200-day simple moving average is $206.52.
Medpace (NASDAQ:MEDP – Get Rating) last issued its quarterly earnings data on Monday, April 24th. The company reported $2.27 EPS for the quarter, topping the consensus estimate of $1.76 by $0.51. The business had revenue of $434.07 million for the quarter, compared to the consensus estimate of $402.83 million. Medpace had a return on equity of 75.20% and a net margin of 16.44%. The firm’s revenue was up 31.2% compared to the same quarter last year. During the same quarter last year, the business posted $1.69 EPS. Research analysts expect that Medpace Holdings, Inc. will post 8.11 EPS for the current year.
About Medpace
(Get Rating)
Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Medpace, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Medpace wasn’t on the list.
While Medpace currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
